GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Capex-to-Revenue

Sinopharm Group Co (Sinopharm Group Co) Capex-to-Revenue : 0.00 (As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Sinopharm Group Co's Capital Expenditure for the three months ended in Sep. 2023 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was $19,864.55 Mil.

Hence, Sinopharm Group Co's Capex-to-Revenue for the three months ended in Sep. 2023 was 0.00.


Sinopharm Group Co Capex-to-Revenue Historical Data

The historical data trend for Sinopharm Group Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Capex-to-Revenue Chart

Sinopharm Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 - - -

Sinopharm Group Co Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sinopharm Group Co's Capex-to-Revenue

For the Medical Distribution subindustry, Sinopharm Group Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's Capex-to-Revenue Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Capex-to-Revenue falls into.



Sinopharm Group Co Capex-to-Revenue Calculation

Sinopharm Group Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-346.763) / 79198.409
=0.00

Sinopharm Group Co's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 19864.548
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (OTCPK:SHTDF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Sinopharm Group Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co (Sinopharm Group Co) Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (Sinopharm Group Co) Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016